• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Lilly, DICE Therapeutics Agree to $2.4B Acquisition Deal


Pharma giant to absorb oral treatment specialist.

Business deal mergers and acquisitions. Image Credit: Adobe Stock Images/vichie81

Image Credit: Adobe Stock Images/vichie81

Eli Lilly and Company has officially announced a deal to acquire DICE Therapeutics, a biopharma organization focused on the creation of novel oral therapeutic candidates to treat chronic diseases in immunology. Approved by the boards of directors for both companies, Lilly is expected to obtain DICE for approximately $2.4 billion.

"In combination with its novel technology and expertise in drug discovery, DICE's talented workforce and passion for innovation will enhance our efforts to make life better for people living with devastating autoimmune diseases," said Patrik Jonsson, EVP, president of Lilly immunology and Lilly USA, chief customer officer. "We welcome DICE colleagues to Lilly and, together, we can tackle the challenges ahead in finding new treatments for patients with significant unmet medical needs."

Reference: Lilly to Acquire DICE Therapeutics to Advance Innovation in Immunology. PR Newswire. June 20, 2023. Accessed June 21, 2023. https://www.prnewswire.com/news-releases/lilly-to-acquire-dice-therapeutics-to-advance-innovation-in-immunology-301854537.html

Related Videos
Related Content